Cargando…
BIRC3 and BIRC5: multi‐faceted inhibitors in cancer
BACKGROUND: The evasion from apoptosis is a common strategy adopted by most tumors, and inhibitors of apoptosis proteins (IAPs) are among the most studied molecular and therapeutic targets. BIRC3 (cellular IAP2) and BIRC5 (survivin) are two of the eight members of the human IAPs family. This family...
Autor principal: | Frazzi, Raffaele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792207/ https://www.ncbi.nlm.nih.gov/pubmed/33413657 http://dx.doi.org/10.1186/s13578-020-00521-0 |
Ejemplares similares
-
Bioinformatics analysis of BIRC5 in human cancers
por: Ye, Han-Bin, et al.
Publicado: (2022) -
Differential regulation of BIRC2 and BIRC3 expression by inflammatory cytokines and glucocorticoids in pulmonary epithelial cells
por: Thorne, Andrew, et al.
Publicado: (2023) -
Increased Expression of BIRC2, BIRC3, and BIRC5 from the IAP Family in Mesenchymal Stem Cells of the Umbilical Cord Wharton's Jelly (WJSC) in Younger Women Giving Birth Naturally
por: Gil-Kulik, Paulina, et al.
Publicado: (2020) -
Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-κB-activating potential
por: Yamato, Azusa, et al.
Publicado: (2015) -
BIRC2–BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia
por: Roohollahi, Khashayar, et al.
Publicado: (2022)